Table 2.

Patients’ treatment and disease characteristics. NK: not known; popPK: population pharmacokinetic; PK/PD: pharmacokinetic/pharmacodynamic.

	Population Used to Build the popPK Model (n = 143)		Population Used to Build the PK/PD Model (n = 128)
	Median (min-max)	Number	Median (min-max)	Number
Number of previous chemotherapies	2 (0–12)		2 (0–12)
Long-term hormonotherapy
Yes		93 (65.0%)		90 (70.3%)
No		40 (28.0%)		38 (29.7%)
NK		10 (7.0%)		0 (0.0%)
Previous radiotherapy
Yes		73 (51.0%)		73 (57.0%)
No		60 (42.0%)		55 (43.0%)
NK		10 (7.0%)		0.0 (0.0%)
Metastases
Yes		108 (75.5%)		105 (82.0%)
No		25 (17.5%)		23 (18.0%)
NK		10 (7.0%)		0.0 (0.0%)
Concurrent hormonotherapy
Fulvestrant		48 (33.6%)		45 (35.2%)
Letrozole		71 (49.6%)		69 (53.9%)
Others		14 (9.8%)		14 (10.9%)
NK		10 (7.0%)		0 (0.0%)